OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Contents
Vear ended 31 December 2025
Page
Legal and administrative information 2
Summary 3
Founder's Statement 5
Report of the Trustees 6
Report of the Independent Auditors 14
Consolidated Statement of Financial Activities 17
Balance Sheets 18
Consolidated Cash Flow Statement 19
Notes forming part of the Financial Statements 20

26/10/2026

Notes
Income
Income from
donations
2
Income from
investments
Total
Expenditure
Charitable
activities
3
Raising funds
4
Total
Net movement
infunds
Transfer of
funds
8
Funds brought
forward
Funds carried
forward
Unrestricted
£
218,750
1,320
220,070
116,790
70,870
187,660
32,410
235,377
267,787
Restricted
£
3,264,413
63,893
3,328,306
1,091,508
13,072
1,104,580
2,223,726
4,890,175
7,113,901
2025
Total
£
3,483,163
65,213
3,548,376
1,208,298
83,942
1,292,240
2,256,136
5,125,552
7,381,688
Unrestricted
£
257,450
257,450
92,494
129,499
221,993
35,457
199,920
235,377
Restricted
£
4,550,018
43,295
4,593,313
1,155,172
33,789
1,188,961
3,404,352
1,485,823
4,890,175
2024
Total
£
4,807,468
43,295
4,850,763
1,247,666
163,288
1,410,954
3,439,809
1,685,743
5,125,552

Notes
Fixed assets
Investments
5
Current assets
Cash at bank
Other debtors
6
Current asset investments
7
Creditors:
Amounts falling due within one year
8
Net current assets
Total assets less current liabilities
Creditors: amounts falling due after
more than one year
9
Total net assets
The funds of the charity
Unrestricted income funds
Restricted income funds
Total funds
Group
2025
2024
£
£
899,841
317,752
4,027,086
1,852,797
90,389
2,119,345
4,500,000
2,500,000
8,617,475
6,472,142
(1,668,905)
(1,169,204)
6,948,570
5,302,938
7,848,411
5,620,690
(466,723)
(495,138)
7,381,688
5,125,552
267,787
235,377
7,113,901
4,890,175
7,381,688
5,125,552
Charity
2025
2024
£
£
899,941
317,852
3,908,795
1,675,292
90,389
2,119,345
4,500,000
2,500,000
8,499,184
6,294,637
(1,550,714)
(991,799)
6,948,470
5,302,838
7,848,411
5,620,690
(466,723)
(495,138)
7,381,688
5,125,552
299,484
267,074
7,082,204
4,858,478
7,381,688
5,125,552
Charity
2025
2024
£
£
899,941
317,852
3,908,795
1,675,292
90,389
2,119,345
4,500,000
2,500,000
8,499,184
6,294,637
(1,550,714)
(991,799)
6,948,470
5,302,838
7,848,411
5,620,690
(466,723)
(495,138)
7,381,688
5,125,552
299,484
267,074
7,082,204
4,858,478
7,381,688
5,125,552
1,675,292
2,119,345
2,500,000
6,294,637
(991,799)
5,302,838
5,620,690
(495,138)
5,125,552
267,074
4,858,478
5,125,552
2025
£
Net movement of funds from operating activities
2,256,136
Impairment of fixed asset investments
100,000
Purchase of fixed asset investments
(682,089)
Increase in debtors/ investments (Notes 6 and 7)
28,956
Increase in creditors (Notes 8 and 9)
471,287
Net cash inflow from operations
2,174,289
Cash at the beginning of the year
1,852,797
Cash at the end of the year
4,027,086
2024
£
3,439,809
100,000
(299,325)
(2,963,898)
233,702
510,288
1,342,509
1,852,797

3.
Charitable activities
Research projects:
University of Minnesota - Nanocol
Gene Editing Trial - UC3 Madrid
Base & Prime Editing strategies for RDEB
University of Colorado - Spray on Skin
EB Cancer Therapy
Oligo
EB Graft
lnserm - SIRNA
JEB Airway Disease
Decorin
Bespoke Therapy
mRNA-based base editing
Chemoprevention
James Lind Alliance
Nanocure
Other costs:
Impairment losses
Support costs:
Administration costs
Bank charges
Audit
Charitable Events - restricted
Research Events - restricted
Insurance
4.
Raising funds
Fund raising and marketing
Fundraising administration costs
2025
£
(26)
(1,525)
38,166
235
326,211
214,843
10,000
358,656
100,000
102,206
272
13,035
44,561
387
1,277
1,208,298
2025
£
36,197
47,745
83,942
2024
£
38,802
350,730
(558,897)
147,033
638,664
66,767
80,000
16,951
267,198
100,000
80,490
274
10,532
6,625
1,300
1,197
1,247,666
2024
£
34,518
128,770
163,288

Fixed asset investments-held by Group and Charity
Social investments-unlisted
Cost at 1 January 2025
Additions
Cost at 31 December 2025
Impairment
Charge for the year
Net book value
At 31 December 2025
At 31 December 2024
Shares in Group undertakings held by Charity
Cost at 1 January 2025
Cost at 31 December 2025
Net book value
Cost at 31 December 2024
2025
£
317,752
682,089
999,841
(100,000)
899,841
317,752
2025
£
100
100
100
2024
£
118,427
299,325
417,752
(100,000)
317,752
118,427
2024
£
100
100
100

Debtors Group Charity
2025 2024 2025 2024
£ £ £ £
Other debtors 90,389 2,119,345 90,389 2,119,345

Current Asset investments
Treasury Bonds
Creditors: amounts falling due within one
year
Trade creditors
Amounts owed to intercompany
Unpaid share capital
Committed grants
Group
2025
2024
£
£
4,500,000
2,500,000
Group
2025
2024
£
£
240,613
258,473
1,428,292
910,731
1,668,905
1,169,204
Charity
2025
2024
£
£
4,500,000
2,500,000
Charity
2025
2024
£
£
18,192
15,005
104,130
65,963
100
100
1,428,292
910,731
1,550,714
991,799
2024
£
2,500,000
991,799

Group
2025
2024
£
£
466,723
495,138
466,723
495,138
Charity
2025
2024
£
£
466,723
495,138
466,723
495,138
Charity
2025
2024
£
£
466,723
495,138
466,723
495,138
495,138
10.
Fund balances- Current year
Balance brought forward
Income
Expenditure
Inter fund transfer
Balance carried forward
Represented by:
Fixed assets
Cash at bank
Other net assets/liabilities
Brought
Current year
Forward
£
Research Projects
Therapy for RDEBsec
50,000
Gene Editing Trial
EB Cancer Therapy
Decorin
SIRNA
37,103
mRNA-based base
editing
James Lind Alliance
Nanocure
Social Investments
Nonsense Therapeutics
100,000
Healome
Eliksa
Replay
FIBRX Derm
Other Social
Investments
118,427
Nova Anchora
99,325
Other Research Funds
Unassigned Research
Funds
557,360
Other Restricted Funds
ABE Fund
424,756
Translational Fund
3,472,549
Ebolution Fund
Funds for Fundraiser
5,280
Research Events
Children's Fund
25,375
4,890,175
Income
£
103,908
200,000
100,000
114,632
74,890
192,568
283,859
304,073
1,525,411
378,165
800
50,000
3,328,306
Expenditure
£
(214,843)
26
1,525
(235)
(326,211)
(10,000)
(358,656)
(13,072)
(38,166)
(387)
(44,561)
(1,004,580)
Unrestricted
Funds
£
235,377
220,070
(187,660)
267,787
267,787
267,787
Gains/Losses
£
(100,000)
(100,000)
Restricted
Funds
£
4,890,175
3,328,306
(1,104,580)
7,113,901
899,841
3,759,299
2,454,761
7,113,901
Transfers
£
164,843
(26)
(1,525)
235
222,303
10,000
358,656
(754,486)
Total
£
5,125,552
3,548,376
(1,292,240)
7,381,688
899,841
4,027,086
2,454,761
7,381,688
Carried
Forward
£
37,103
200,000
100,000
114,632
74,890
192,568
118,427
99,325
86,733
715,757
4,959,794
378,165
5,280
413
30,814
7,113,901
Total
£
5,125,552
3,548,376
(1,292,240)
7,381,688
899,841
4,027,086
2,454,761
7,381,688
Carried
Forward
£
37,103
200,000
100,000
114,632
74,890
192,568
118,427
99,325
86,733
715,757
4,959,794
378,165
5,280
413
30,814
7,113,901
7,113,901
10
Fund balances (Continued)
Previous Year
Balance brought forward
Income
Expenditure
Inter fund transfer
Balance carried forward
Represented by:
Fixed assets
Cash at bank
Other net assets/liabilities
Brought
Previous year
Forward
£
Research Projects
Therapy for RDEB~~sec~~
50,000
EB Graft
Gene Editing Trial
Spray on Skin
Base & prime editing
strategies for RDEB
EB Cancer Therapy
Bespoke Therapy
JEB Airway Disease
Decorin
SIRNA
Social Investments
Nonsense
Therapeutics (ABE
Fund)
Other Social
Investments
118,427
Nova Anchora
Other Research Funds
Unassigned Research
Funds
198,300
Other Restricted
Funds
ABE Fund
26,818
Translational Fund
1,086,078
Funds for Fundraiser
6,200
Research Events
Children's Fund
1,485,823
Income
£
37,103
108,631
37,103
200,000
99,325
621,910
412,807
3,025,134
1,300
50,000
4,593,313
Expenditure
£
(66,767)
(38,802)
558,897
(350,730)
(147,033)
(267,198)
(80,000)
(16,951)
(14,869)
(638,663)
(920)
(1,300)
(24,625)
(1,088,961)
Unrestricted
Funds
£
199,920
257,450
(221,993)
235,377
235,377
235,377
Gains/Losses
£
(100,000)
(100,000)
Restricted
Funds
£
1,485,823
4,593,313
(1,188,961)
4,890,175
317,752
1,617,420
2,955,003
4,890,175
Transfers
£
66,767
38,802
(596,000)
242,099
147,033
267,198
80,000
16,951
(262,850)
Total
£
1,685,743
4,850,763
(1,410,954)
5,125,552
317,752
1,852,797
2,955,003
5,125,552
Carried
Forward
£
50,000
37,103
100,000
118,427
99,325
557,360
424,756
3,472,549
5,280
25,375
4,890,175
Therapy for RDEB~~sec~~
EB Graft
Gene Editing Trial
Spray on Skin
Base & prime editing
strategies for RDEB
EB Cancer Therapy
Bespoke Therapy
JEB Airway Disease
Decorin
SIRNA
Social Investments
Nonsense
Therapeutics (ABE
Fund)
Other Social
Investments
Nova Anchora
Other Research Funds
Unassigned Research
Funds
Other Restricted
Funds
ABE Fund
Translational Fund
Funds for Fundraiser
Research Events
Children's Fund